Navigation Links
Oligomerix, Inc. Completes Series B Financing
Date:5/22/2013

NEW YORK, May 22, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the completion of its Series B financing, which includes both issuance of new convertible preferred shares and warrants that would represent approximately $2.8M in new investments in the Company.  Both current investors and new investors supported the raise.

Funding from the Series B round will allow Oligomerix to rapidly advance its drug discovery programs targeting tau protein oligomers that have recently been shown to be neurotoxic, impair memory formation and cause disease progression in disease models.  The Company is developing small molecule inhibitors of tau oligomer formation and antibodies specific for tau oligomer structure that have potential biomarker, diagnostic and therapeutic applications.  Oligomerix has discovered that tau becomes a proteolytic enzyme upon forming an oligomer structure that causes it and other proteins to fragment.  Based on this unique mechanistic insight into the toxicity of tau oligomers, Oligomerix is developing small molecule inhibitors of this activity and antibodies specific for tau's self-cut ends for biomarker and therapeutic uses.

James Moe , Ph.D., MBA, president and CEO of Oligomerix, Inc., commented, "We are pleased that our investors continue to believe in the breakthrough research Oligomerix is conducting across our core programs and that we have several new investors participating in this round.  We have demonstrated ongoing key developments in both our tau aggregation inhibitor and tau protease small molecule programs as well as in developing novel antibodies for each program.  Our research has shown that extracellular tau oligomers impair memory formation in animal studies.  Recent pivotal papers from other research laboratories indicate that tau oligomers may be involved in disease transmission. Therefore, neutralizing extracellular tau holds promise both for improving cognitive function and for interrupting disease progression in Alzheimer's."  

ABOUT ALZHEIMER'S DISEASE
Alzheimer's disease, the most common form of dementia, is increasing worldwide due to demographic shifts in the aging population.  Hallmark abnormalities for Alzheimer's disease are deposits of the protein fragment beta-amyloid (plaques) and twisted strands of the protein tau (tangles) as well as evidence of nerve cell damage and brain death.

The Alzheimer's Association estimates there are 5.4 million Alzheimer's disease sufferers in the U.S.  It is the most costly disease today with more than $215 billion in annual costs and growing rapidly to greater than $1.1 trillion by 2050.  There are no FDA-approved therapeutics that alter the course of the disease or slow its progression.  The recent findings that tau oligomers are involved in the spread of pathology in disease progression validates extracellular tau oligomers.

ABOUT OLIGOMERIX
Oligomerix, Inc. is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center. The Company is seeking strategic partners to help accelerate these exciting programs.  For more information visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.

CONTACTS:
Oligomerix, Inc.
Jack Pasini
Chief Commercial Officer
917-912-4088
jpasini@oligomerix.com

Tiberend Strategic Advisors, Inc. 
Andrew Mielach
212-375-2694
amielach@tiberend.com


'/>"/>
SOURCE Oligomerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Leviticus Cardio Ltd. Completes a Successful Animal Trial for its Wireless Energy System for VADs
3. St. Mary Completes Phase 2 of Its Emergency Department and Trauma Center Expansion
4. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
5. bioRASI Completes Acquisition of Ukrainian CRO
6. Novira Therapeutics Completes $25 Million Series A Financing
7. BGI-Shenzhen Completes Acquisition of Complete Genomics
8. Amarantus Completes Name Change and CUSIP Change
9. Advanced Cell Diagnostics Completes $12 Million Series B Financing
10. Synthetic Biologics Completes $10.8 Million Private Placement Financing
11. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... KY and San Diego, CA (PRWEB) , ... April 29, 2016 ... ... National Stem Cell Foundation (NSCF) to support the development of a patient-specific stem cell ... Dr. Andrés Bratt-Leal in the lab of Dr. Jeanne Loring at The Scripps Research ...
(Date:4/28/2016)... The report "Cryocooler Market by ... (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, and ... 2022", published by MarketsandMarkets, the global market is expected ... a CAGR of 7.29% between 2016 and 2022. ... Figures spread through 159 Pages and in-depth TOC on ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... deliver a talk on its first-in-class technologies for tissue stem cell counting and ... on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , ...
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, ... web technology, today announced that it has been named to The Silicon Review’s “20 ... services and other markets, Cambridge Semantics serves the needs of end users facing some ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):